ArticleBMC cancer2026
Optimizing chemotherapy regimens and dosing for older patients with metastatic pancreatic cancer: insights from the Tokushukai real-world data project.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundEvidence regarding the efficacy and tolerability of chemotherapy in older patients with pancreatic cancer remains insufficient. This study aimed to determine the optimal chemotherapy regimen and relative dose intensity (RDI) in older patients with pancreatic cancer.
methodsThis retrospective analysis included patients aged ≥ 75 years with metastatic pancreatic cancer treated with gemcitabine plus nab-paclitaxel (GnP) or gemcitabine (Gem) monotherapy, using data from the Tokushukai Real-World Data project. Patients were categorized by RDI into high (≥ 85%), middle (> 50, < 85%), and low (≤ 50%) groups. Hazard ratios with 95% confidence intervals for overall survival were estimated using multivariate Cox proportional hazards regression models to evaluate the impact of each covariate on overall survival.
resultsA total of 153 patients were identified. More patients in the Gem group had a performance status of ≥ 2 (13.4% vs. 5.4%). There were slightly more patients aged ≥ 80 years in the Gem group, but no significant differences in sex, nutritional indices, body mass index, smoking history, or initial chemotherapy dosage. The median overall survival was longer in the GnP group (9.1 months vs. 6.1 months, p = 0.02). Patients in the GnP-middle RDI group had the best overall survival (median, 11.0 months, p = 0.01). Cox regression identified GnP-middle RDI, performance status, modified Glasgow Prognostic Score, and high body mass index as significant factors for prolonged overall survival.
conclusionsMaintaining a medium RDI of GnP resulted in better overall survival than maintaining a high RDI GnP or Gem monotherapy in older patients with metastatic pancreatic cancer. These findings emphasize balancing treatment intensity with tolerability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.